“…Although the mechanisms of GI symptoms in CF have not been investigated in detail, it is known that guanylyl cyclase (GC) is involved in the pathogenesis of CF, as it is known to be implicated in functional or chronic idiopathic constipation. As linaclotide—recently approved for the indication to IBS‐C and chronic idiopathic constipation in some countries including Japan 7 , 8 —blocks GC and improves complete spontaneous bowel movements, fecal condition, and abdominal pain/discomfort, this drug would be also expected to be useful in the treatment of constipation symptoms in CF. Further understanding of GI symptom generation, pathophysiological origins, and assessment method for monitoring symptoms will be necessary to apply this agent to the possible treatment of CF.…”